Research Article
Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study
Table 3
Characteristics of the treatments.
| | Characteristics | | Patients () |
| | Chemotherapy regimens, (%) | TP# | 20 (76.9) | | Others | 6 (23.1) |
| | Combine with Endostar, (%) | Yes | 14 (53.8) | | No | 12 (46.2) |
| | Number of induction chemotherapy cycles, (%) | 0 | 3 (11.5) | | 1 | 4 (15.4) | | 2 | 16 (61.5) | | ≥3 | 3 (11.5) |
| | Radiation therapy, (%) | One-stage strategy | 13 (50) | | Two-stage strategy | 13 (50) |
| | Radiation dose (cGy) | Median (range) | 6800 (6620-6930) | | >6800, (%) | 7 (26.9) | | ≤6800, (%) | 19 (73.1) |
|
|
#TP, paclitaxel+nedaplatin. Other chemotherapy regimens included TPF (paclitaxel+nedaplatin+S-1, ); DPF (docetaxel+nedaplatin+S-1, ); NP (vinorelbine+cisplatin, ); PP (pemetrexed+nedaplatin, ); vinorelbine+S-1, ; S-1 monotherapy, . |
